Case Report: Metastatic melanoma with initial ctdna decline and radiographic response during self-directed antiparasitic use: treatment effect or spontaneous regression? (2026)

Peer-Reviewed Study · Richard Cheng, Diego V. Araujo · September 1, 2026

Richard Cheng et al., 2026-09-01: Case report of a 74-year-old man with metastatic nodular melanoma whose ctDNA and scans improved then worsened while he self-administered ivermectin and fenbendazole; the authors state spontaneous immune-mediated regression is at least as plausible as any drug effect.

He declined guideline-directed therapy and instead pursued lifestyle modifications alongside self-administered ivermectin and fenbendazole.

Richard Cheng et al., 2026-09-01: Case report of a 74-year-old man with metastatic nodular melanoma whose ctDNA and scans improved then worsened while he self-administered ivermectin and fenbendazole; the authors state spontaneous immune-mediated regression is at least as plausible as any drug effect. C3. Study type: single case report, n=1, United States (University of Florida). No comparator. Dose: not stated in the abstract (self-administered ivermectin and fenbendazole); product/maker not named. Other treatment: lifestyle modification only; he declined guideline therapy. Outcome as measured: tumour-informed ctDNA (Signatera) fell from 2.04 to 0.18 MTM/mL with reduced metabolic activity and size on imaging, then rose to 0.93 MTM/mL with the dominant axillary nodal mass enlarging; tumour mutational burden at least 50 mutations/Mb. Funding: not stated. Disclosures: 'DA reports grants/research support from Amgen, Exelixis, and MSD Oncology; and honoraria from Tersera and AstraZeneca' – the treating-author disclosure, unrelated to antiparasitics. The paper's own conclusion is that the case does not establish efficacy; recorded at full strength in both directions. Also filed as IVD-53 (claims C3, C7). Study type: case report.